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Balancing Immunity and 
Immunosuppression:  
Vaccinating Patients Receiving 
Treatment with Efalizumab
Shana Marmon1 and Bruce E. Strober2
Although effective in the treatment of immunodysregulatory diseases such as 
psoriasis, targeted immunosuppressive agents may confer risks of both enhanced 
susceptibility to infection and decreased responsiveness to vaccination. In a recent 
study, Krueger et al. (this issue) investigated these issues by testing the immune 
response to both a model antigen and a therapeutic vaccination in psoriasis 
patients during and after treatment with an LFA-1 inhibitor, efalizumab.
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Targeted therapeutics that act on specif­
ic steps in the immunological cascade 
have rapidly moved to the forefront of 
psoriasis therapy. These drugs, known 
as biologicals, variously function by 
interfering with costimulation, cyto­
kines, and other molecules involved in 
the activation or effector functions of 
the adaptive immune system. A num­
ber of clinical studies have established 
the efficacy of these agents, which in 
many cases outperformed standard 
disease­modifying antirheumatic drugs 
such as methotrexate, with apparently 
fewer toxic side effects (Kipnis et al., 
2005).
Efalizumab, a humanized mono­
clonal antibody specific for the integrin 
CD11a, is a biological agent that func­
tions by blocking costimulation and 
inhibiting the activation of naive T cells. 
One concern regarding costimulation­
inhibiting agents is the theoretical risk 
of developing anergy (T­cell nonre­
sponsiveness) in the setting of either 
primary infection or vaccination. The 
recent study by Krueger et al. (this issue) 
addresses these concerns by character­
izing the humoral and cellular immune 
response to model antigens and 
commonly used vaccines in psoriatic 
patients treated with efalizumab.
The pathophysiology of psoriatic 
disease involves the influx of activated 
T cells into affected tissues, primarily 
skin and joints. Efalizumab, a human­
ized monoclonal antibody, inhibits at 
least two steps during the pathogenesis 
of psoriasis. By binding to CD11a, the 
α­chain of LFA­1, and blocking interac­
tion with ICAM­1, efalizumab disrupts 
the formation of the immunological 
synapse, a critical step in antigen­
dependent T­cell activation. Primary 
activation of naive T cells, also known 
as T­cell priming, requires two signals. 
The first is provided by the engagement 
of the TCR and a peptide­bound major 
histocompatibility complex molecule. 
Signal 2, also known as the costimula­
tory signal, involves the concomitant 
interaction between T­cell­associated 
molecules such as ICAM­1 and CTLA­4 
with their respective ligands, LFA­1 and 
B7, molecules expressed on the sur­
face of professional antigen­presenting 
cells (Anderson and Siahaan, 2003). 
Specific blockade of the costimulatory 
signal leads to suboptimal activation 
and elicits a state in which the T cell 
is refractory to a subsequent antigenic 
stimulus, or “anergized.” Indeed, in pre­
clinical studies conducted in rodents, 
efalizumab induced antigen­specific 
tolerance to cardiac grafts. However, 
these effects were tissue specific, as no 
tolerizing effect was observed for skin 
grafts (Cavazzana­Calvo et al., 1995).
To explore some of the immunologic 
consequences of efalizumab therapy 
in humans, Krueger and colleagues 
(2008) performed a randomized con­
trolled study of subjects with moderate 
to severe plaque psoriasis, examining 
responses to a range of antigens during 
and after treatment. As anticipated, efal­
izumab therapy resulted in substantially 
decreased CD11a expression on the 
surfaces of both B and T cells. However, 
following complete clearance of the 
drug 7 weeks after the last dose, CD11a 
expression was restored to levels com­
parable to those observed in placebo­
treated subjects, indicating that there 
was no residual effect on expression fol­
lowing discontinuation of the drug.
To evaluate the effect of efalizumab 
on antibody production, both drug­ and 
placebo­treated groups were inoculated 
with the model antigen bacteriophage 
phiX174. In the presence of therapeutic 
levels of efalizumab, there was a nearly 
10­fold decrease in the primary B­cell 
IgM response, which that persisted dur­
ing the follow­up period. Nonetheless, 
antibody titers in the treated group 
were sufficient to clear the phage with­
in minutes of immunization. As might 
be expected, there was also near com­
plete blockade of IgM­to­IgG isotype 
switching, indicating that efalizumab 
may impair naive T­cell activation. 
However, discontinuation of the drug 
resulted in a small but statistically sig­
nificant increase in IgG compared with 
the level in placebo­treated subjects. 
The clinical significance of this diminu­
tion of IgG is unknown.
The authors also investigated the 
response to immunization with pneu­
mococcus vaccine and tetanus toxoid. 
The two vaccines are quite dissimilar 
and examine different capabilities of the 
immune system. The polysaccharide­
based pneumococcus vaccine has been 
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effect on the immune system. As with 
patients receiving efalizumab, post–
cardiac transplant patients treated with 
cyclosporine responded appropriately 
to immunization with pneumococcus, 
whereas the response to the protein­
based influenza vaccine was impaired 
(Dengler et al., 1998). It is thus logical 
to surmise that the combination of mul­
tiple T­cell targeting agents could result 
in a more significant impairment of 
immunity to pathogens and could fur­
ther diminish the efficacy of vaccines in 
these populations.
It is also important to note that the 
biological response to vaccination 
observed with this agent cannot be 
extrapolated to other psoriasis therapeu­
tics with different mechanisms of action. 
A similar study in psoriatic patients 
investigating the immune response to 
phiX174 while under treatment with 
alefacept, an LFA­3/IgG1 fusion protein, 
demonstrated no effect on naive T cells 
or interference with primary or second­
ary humoral immune response (Gottlieb 
et al., 2003). A trial using rituximab, an 
inhibitor of CD20 on B lymphocytes, 
resulted in a larger decrease in antibody 
response to bacterio phage phiX174 
when administered to subjects with 
chronic renal failure. In fact, one sub­
ject developed partial tolerance to the 
antigen (Bearden et al., 2005).
The study by Krueger et al. (2008) 
describes the immune response to 
a comprehensive set of antigens in 
patients under treatment with the 
immunomodulatory agent efalizumab 
and may assist in the development of 
updated and rational guidelines for the 
vaccination of patients receiving this 
drug. This study sets an example as to 
how newly developed, specifically 
targeted biological agents should be 
evaluated with regard to the effect not 
only on the response to immunization 
but also on the potential risk of infec­
tion during therapy.
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immune response with the rapid gen­
eration of antibody and absence of 
B­cell memory. In contrast, tetanus 
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Aside from participating in the gen­
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and memory T­cell homing to the 
affected tissue. To measure DTH, pla­
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injected intracutaneously with two 
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Surprisingly, while under treatment 
with efalizumab, subjects displayed 
only a slightly diminished response to 
tetanus and had a response to candida 
equivalent to that found in the place­
bo­treated group. Thus, only a mini­
mal effect on this aspect of immune 
status was noted.
|T­cell targeting  agents require considerable study.
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A Role for Th17 cells  
in the Immunopathogenesis  
of Atopic Dermatitis?
Antonella Di Cesare1,2, Paola Di Meglio1, and Frank O. Nestle1
Atopic dermatitis (AD) is a common inflammatory skin disease. Both epidermal 
barrier dysfunction and immunodysregulation are suggested to influence the 
pathogenesis of AD. AD has been considered a paradigmatic T helper cell (Th) 
2–mediated disease, with a switch to a Th1 cell environment during the chronic 
phase of the disease. Previously unreported findings now suggest a possible role 
for Th17 cells as well.
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Atopic dermatitis (AD) is a common, 
chronic relapsing, inflammatory skin 
disease often associated with other sys­
temic atopic disorders such as asthma, 
food allergy, and allergic rhinitis. The 
pathogenesis of AD has been attributed 
to a complex interaction among the envi­
ronment and host susceptibility genes, 
altered skin barrier function, and the 
immune system (Bieber, 2008). Typically, 
AD has been considered the paradigm 
of an allergic T helper (Th) 2–mediated 
disease, characterized by abnormal IgE 
production, peripheral eosinophilia, 
mast cell activation, and induction of 
Th2 lymphocytes expressing IL­4, IL­10, 
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and IL­13 but not IFN­γ (Wierenga et 
al., 1991). However, observations on 
the clinical evolution of the cutaneous 
lesions from an acute phase (character­
ized by erythematous papules, intense 
itching, excoriation, and serous exuda­
tion) to a chronic phase (with lichenifica­
tion) led to the development of models 
to study the progression of the disease. 
Sequential biopsies in AD patients after 
exposure to aeroallergens demonstrated 
a biphasic immunologic response char­
acterized by antigen presentation, Th2 
activation, IgE release, eosinophil recruit­
ment, and a switch toward a Th1 pheno­
type in later phases of the disease (Grewe 
et al., 1995). Eosinophils, together with 
infiltrating dendritic cells, are thought to 
be responsible for the Th2­to­Th1 switch.
Recently, the Th1/Th2 paradigm in 
autoimmunity and allergy has been revis­
ited, including a role for a new popula­
tion of IL­17–producing Th cells (Th17) 
(Weaver et al., 2007). Transforming 
growth factor (TGF)­β, IL­1β, IL­6, and 
IL­23 seem to be key factors involved in 
naive Th­cell commitment to a Th17 phe­
notype, distinguishing Th17 cells from 
Th1 and Th2 populations. Moreover, 
Th17 cells are characterized by the pro­
duction of inflammatory cytokines such 
as IL­17A, IL­17F, IL­22, and IL­26. Th17 
cells have been implicated in several 
human autoimmune diseases, including 
multiple sclerosis, rheumatoid arthritis, 
inflammatory bowel disease, and psoria­
sis, as well as in the clearance of extracel­
lular pathogens (e.g., Candida albicans, 
Borrelia burgdoferi, Mycobacterium 
tuberculosis, and Streptococcus pneu-
moniae) (Tesmer et al., 2008).
The role of Th17 cells in allergy is 
still largely unresolved. Increased lev­
els of IL­17A have been reported in the 
peripheral blood, sputum, and airways of 
asthmatic patients and have been corre­
lated with the degree of bronchial hyper­
reactivity (Tesmer et al., 2008). IL­17A, 
|IL­17 and Th17 cells may have roles in AD.
